Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16443 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Jun Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc, Foster City, California, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Hypolipidemic Agents, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Aims
The impact of antidiabetic and lipid‐lowering medications on fibrosis in patients with metabolic dysfunction‐associated steatohepatitis (MASH) is poorly understood. We evaluated associations between the use of these medications and serum liver fibrosis biomarkers, and whether they vary by genetic factors. Materials and Methods This cross‐sectional study used baseline medication and fibrosis biomarker (aspartate aminotransferase‐to‐platelet ratio index [APRI], Enhanced Liver Fibrosis [ELF], Fibrosis‐4 Index (FIB‐4) and FibroSure/FibroTest) data from two phase 3 trials ( N = 1649) of MASH with bridging fibrosis (NCT03053050, N = 785) or compensated cirrhosis (NCT03053063, N = 864). A weighted polygenic risk score (wPRS) for MASH was derived for participants of European ancestry ( N = 742) using six genetic variants. Least‐squares means and 95% confidence interval (CIs) were derived using multivariable linear regression.
Results
Combined use of antidiabetic and lipid‐lowering medications was associated with statistically significantly lower adjusted mean ELF (−0.34 [95% CI: −0.47, −0.20] or − 3.2%), FIB‐4 (−0.53 [95% CI: −0.74, −0.32] or − 18.0%), APRI (−0.27 [95% CI: −0.37, −0.18] or − 23.1%) and FibroSure/FibroTest scores (−0.08 [95% CI: −0.11, −0.06] or − 14.7%) compared with nonuse. Among participants of European ancestry, the inverse association for FIB‐4 (interaction p = 0.01) or APRI (interaction p = 0.004) was stronger in participants with high (>median) versus low (≤median) wPRS; no significant interactions were observed for ELF or FibroSure/FibroTest.
Conclusions
Antidiabetic and lipid‐lowering medication use was associated with lower serum liver fibrosis biomarkers. Among participants with European ancestry, associations between combined use of these medications and lower FIB‐4 or APRI scores were stronger in those at high genetic risk of MASH. Longitudinal studies are warranted to extend upon these potentially clinically important findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc, Foster City, California, USA.
ORCID-Profile: Jun Wang
Förderung
- Gilead Sciences
Zitieren
APA
Wang, J., Ding, D., Shao, X., Ma, L., Xu, J., Melehani, J., Boyette, L., Watkins, T. R., Jia, C., Malkov, V. A., Billin, A. N., & Iqbal, S. (2025). Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16443
Vancouver
Wang J, Ding D, Shao X, Ma L, Xu J, Melehani J, et al. Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16443
BibTeX
@article{Wang2025,
author = {Wang, Jun and Ding, Dora and Shao, Xiaorong and Ma, Lily and Xu, Jun and Melehani, Jason and Boyette, Lisa and Watkins, Timothy R and Jia, Catherine and Malkov, Vladislav A and Billin, Andrew N and Iqbal, Shahed},
title = {Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16443}
}
EUVIMED